Investegate |Syncona Limited Announcements | Syncona Limited: Achilles reports Q4 and full year 2022 Results
Investegate announcements from Syncona Limited, Achilles reports Q4 and full year 2022 Results
Stay updated with breaking news from Achilles Clonality Engine. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investegate announcements from Syncona Limited, Achilles reports Q4 and full year 2022 Results
Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies to treat solid tumors, today announced that United States (US) patent 11,504,398 has been granted. The patent covers the treatment of patients with an immunotherapy targeting clonal ...
- US patent is for an immunotherapy targeting clonal neoantigens identified by the Achilles Clonality Engine (ACE), including vaccine, antibody, and autologous T cell therapy approaches -LONDON, Nov. 22